Vical Announces Breakthrough For Pandemic Influenza DNA Vaccines With Preliminary Human Data
Vical Incorporated (Nasdaq: VICL) announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans.

















